drugset / Trial / NCT00357500

Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer

NCT00357500

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.

Timeline

Start
2005-01
Primary completion
2013-02
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 100 mg Oral
Subject Celecoxib Other / unclassified 200 mg Oral
Subject Celecoxib Other / unclassified 400 mg Oral
Subject Cyclophosphamide Other / unclassified 2.5 mg/kg Oral
Subject Etoposide Small molecule 50 mg/m2 Oral
Subject Fenofibrate Small molecule 90 mg/m2 Oral
Subject Thalidomide Other / unclassified 24 mg/kg Oral